All News 3D Medicines Inc.

Equities

1244

KYG8872R1011

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-06-05 EDT			5-day change	1st Jan Change
6.3 ^HKD	-1.10%		-11.02%	-17.54%

02:45pm	3D Medicines to Appoint New Auditors	MT
03-29	3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

3D Medicines to Appoint New Auditors	08:45am	MT
3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	03-29	MT
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	02-19	MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	02-19	MT
3D Medicines Inc. commences an Equity Buyback Plan for 25,605,700 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2023.	01-31	CI
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 for Multiple Geographies around the World	01-26	AQ
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	01-24	CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	01-24	MT
3D Medicines Unit Receives Repayment for 60 Million Yuan Loan	01-22	MT
3D Medicines Subsidiary Extends 60 Million Yuan Loan; Shares Fall 3%	01-04	MT
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	12-27	MT
3D Medicines Inc. Announces Change of Principal Place of Business in Hong Kong	12-26	CI
35,992,364 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2023.	12-13	CI
3D Medicines Gets US FDA's Nod to Trial Envafolimab; Shares Soar 24%	23-10-30	MT
3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer	23-10-29	CI
Sellas Life Sciences Expects to Complete Patient Enrollment for Phase 3 REGAL Trial in November	23-10-12	MT
128,967,484 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	23-09-29	CI
3D Medicines Invests Over $21 Million of Surplus Cash	23-09-26	MT
3D Medicines Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News 3D Medicines Inc.

Equities

1244

KYG8872R1011

All News

Filters